<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176904</url>
  </required_header>
  <id_info>
    <org_study_id>MT1995-01</org_study_id>
    <nct_id>NCT00176904</nct_id>
    <nct_alias>NCT00005894</nct_alias>
  </id_info>
  <brief_title>Stem Cell Transplant for Inborn Errors of Metabolism</brief_title>
  <official_title>Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and engraftment of donor hematopoietic
      cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming)
      cell transplant for an inherited metabolic storage disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to transplantation, subjects will receive Busulfan intravenously (IV) via the Hickman
      line four times daily for 4 days, Cyclophosphamide intravenously via the Hickman line once a
      day for 4 days, and Anti-Thymocyte Globulin (ATG) intravenously (IV) via the Hickman line
      twice daily for three days before the transplant. These three drugs are being given to
      subjects to help the new marrow &quot;take&quot; and grow.

      On the day of transplantation, the donor's hematopoietic cells will be transfused via central
      venous catheter.

      After hematopoietic cell transplant, subjects will then receive two drugs, cyclosporin and
      either methylprednisolone or Mycophenolate Mofetil (MMF). Cyclosporin and methylprednisolone
      or MMF are given to help prevent the complication of graft-versus-host disease and to
      decrease the chance that the new donor cells will be rejected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1995</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>100 Days, 1 Year and 3 Years</time_frame>
    <description>Number of patients alive at designated timepoints after transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Donor Engraftment</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of patients with full donor chimerism (state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease) by Day 100 post-transplant of at least 90%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade II-IV Acute Graft-Versus-Host Disease</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of patients who exhibited acute graft-versus-host disease by Day 100 post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Grade I=mild, Grade II=moderate, Grade III=severe, Grade IV=life threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade III-IV Acute Graft-Versus-Host Disease</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of patients who exhibited acute graft-versus-host disease by Day 100 post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Grade I=mild, Grade II=moderate, Grade III=severe, Grade IV=life threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Chronic Graft-Versus-Host Disease</measure>
    <time_frame>1 Year Post Transplant</time_frame>
    <description>Number of patients who exhibited chronic graft-versus-host disease by 1 Year post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Chronic GVHD is an extension of this syndrome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Adrenoleukodystrophy</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <condition>Globoid Cell Leukodystrophy</condition>
  <condition>Gaucher's Disease</condition>
  <condition>Fucosidosis</condition>
  <condition>Wolman Disease</condition>
  <condition>Niemann-Pick Disease</condition>
  <condition>Batten Disease</condition>
  <condition>GM1 Gangliosidosis</condition>
  <condition>Tay Sachs Disease</condition>
  <condition>Sandhoff Disease</condition>
  <arm_group>
    <arm_group_label>Treated Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients treated with protocol regimen (chemotherapy and surgery).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Bone marrow transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Cyclophosphamide, Antithymocyte Globulin</intervention_name>
    <description>Subjects will receive BUSULFAN intravenously (IV)- patients &lt; or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients &gt; 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow &quot;take&quot; and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Busulfex, Cytoxan, ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell
             leukodystrophy, Gaucher's disease, Fucosidosis, Wolman disease, Niemann-Pick disease
             and Batten disease (CLN3) who have a human leukocyte antigen (HLA)-identical or
             haplotype mismatched (at 1-3 antigens) related marrow, or umbilical cord blood donor.
             One or two umbilical cord blood (UCB) units may be used.

          -  Patients with GM1 gangliosidosis, Tay Sachs disease or Sandhoff disease who have a
             HLA-identical or 1 antigen mismatched related or unrelated donor, or suitably matched
             umbilical cord blood unit(s). One or two UCB units may be used.

          -  Patients with adrenoleukodystrophy must have magnetic resonance imaging (MRI)
             findings, neurological and neuropsychometric function consistent with the diagnosis,
             and for boys with parietal-occipital dysmyelination a performance intelligence
             quotient (IQ) ≥80. In cases, when the performance IQ is not ≥80, the protocol
             committee may recommend transplant if the patient's clinical condition and
             neuropsychometric status are deemed to be acceptable based upon consideration of such
             factors as age at onset of cerebral disease, magnitude of change in performance IQ and
             neurologic deficits.

          -  Patients with arylsulfatase A deficiency (Metachromatic Leukodystrophy) must have
             either the presymptomatic late infantile, juvenile or adult form of the disease and
             must have acceptable neurological and neuropsychometric function.

          -  Patients with galactocerebrosidase deficiency (Globoid Cell Leukodystrophy) must have
             acceptable neurological and neuropsychometric function.

          -  Patients with acid lipase deficiency (Wolman disease) must have a liver biopsy that
             documents no evidence of hepatic cirrhosis, and acceptable neurological and
             neuropsychometric function.

          -  Patients with fucosidase deficiency (Fucosidosis) must have acceptable neurological
             and neuropsychometric function.

          -  Patients with glucocerebrosidase deficiency (Gaucher's Disease) must have acceptable
             neurologic and neuropsychometric function.

          -  Patients with Batten's disease (CLN3) must have acceptable Neurological and
             neuropsychometric function.

          -  Absence of major organ dysfunction. Organ evaluation results as follows:

          -  Cardiac: ejection fraction &gt;30%

          -  Renal: serum creatinine &lt;2x normal or creatinine clearance 60 mL/min.

          -  Hepatic: total bilirubin &lt;2x normal and Aspartate aminotransferase (AST) &lt;2x normal

          -  Signed consent.

        Exclusion Criteria:

          -  Patients with symptomatic late infantile form of metachromatic leukodystrophy.

          -  Patients with symptomatic infantile globoid leukodystrophy.

          -  Note: Patients with Hurler syndrome, mucopolysaccharidosis (MPS) VI, or Mannosidosis
             disease are no longer eligible for this protocol, but can be transplanted under
             protocol MT 9907 (NCT00176917 - Hematopoietic Cell Transplantation for Hurler
             Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency
             (Mannosidosis)).

          -  Pregnancy

          -  Evidence of human immunodeficiency virus (HIV) infection or known HIV positive
             serology

          -  Patients or parents are psychologically incapable of undergoing bone marrow transplant
             (BMT) with associated strict isolation or documented history of medical
             non-compliance.

          -  Patients ≥ 50 kg may be at risk for having cell doses below the goal of ≥ 10 x 10^6
             CD34 cells/kg and therefore will not be eligible to receive unrelated peripheral blood
             stem cells (PBSCs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Orchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>May 17, 2011</results_first_submitted>
  <results_first_submitted_qc>May 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2011</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inborn errors</keyword>
  <keyword>Storage disease</keyword>
  <keyword>errors of metabolism</keyword>
  <keyword>stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
    <mesh_term>Gangliosidoses</mesh_term>
    <mesh_term>Tay-Sachs Disease</mesh_term>
    <mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
    <mesh_term>Wolman Disease</mesh_term>
    <mesh_term>Sandhoff Disease</mesh_term>
    <mesh_term>Leukodystrophy, Globoid Cell</mesh_term>
    <mesh_term>Gangliosidosis, GM1</mesh_term>
    <mesh_term>Fucosidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Treated With Stem Cell Transplant</title>
          <description>All patients treated with protocol regimen (chemotherapy and stem cell transplant).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Treated With Stem Cell Transplant</title>
          <description>All patients treated with protocol regimen (chemotherapy and stem cell transplant).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Number of patients alive at designated timepoints after transplant.</description>
        <time_frame>100 Days, 1 Year and 3 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Stem Cell Transplant</title>
            <description>All patients treated with protocol regimen (chemotherapy and stem cell transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of patients alive at designated timepoints after transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Donor Engraftment</title>
        <description>Number of patients with full donor chimerism (state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease) by Day 100 post-transplant of at least 90%.</description>
        <time_frame>Day 100</time_frame>
        <population>1 Patient not included due to early death (before day 40).</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Stem Cell Transplant</title>
            <description>All patients treated with protocol regimen (chemotherapy and stem cell transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Donor Engraftment</title>
          <description>Number of patients with full donor chimerism (state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease) by Day 100 post-transplant of at least 90%.</description>
          <population>1 Patient not included due to early death (before day 40).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade II-IV Acute Graft-Versus-Host Disease</title>
        <description>Number of patients who exhibited acute graft-versus-host disease by Day 100 post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Grade I=mild, Grade II=moderate, Grade III=severe, Grade IV=life threatening.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Stem Cell Transplant</title>
            <description>All patients treated with protocol regimen (chemotherapy and stem cell transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade II-IV Acute Graft-Versus-Host Disease</title>
          <description>Number of patients who exhibited acute graft-versus-host disease by Day 100 post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Grade I=mild, Grade II=moderate, Grade III=severe, Grade IV=life threatening.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade III-IV Acute Graft-Versus-Host Disease</title>
        <description>Number of patients who exhibited acute graft-versus-host disease by Day 100 post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Grade I=mild, Grade II=moderate, Grade III=severe, Grade IV=life threatening.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Stem Cell Transplant</title>
            <description>All patients treated with protocol regimen (chemotherapy and stem cell transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade III-IV Acute Graft-Versus-Host Disease</title>
          <description>Number of patients who exhibited acute graft-versus-host disease by Day 100 post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Grade I=mild, Grade II=moderate, Grade III=severe, Grade IV=life threatening.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Chronic Graft-Versus-Host Disease</title>
        <description>Number of patients who exhibited chronic graft-versus-host disease by 1 Year post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Chronic GVHD is an extension of this syndrome.</description>
        <time_frame>1 Year Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Stem Cell Transplant</title>
            <description>All patients treated with protocol regimen (chemotherapy and stem cell transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Chronic Graft-Versus-Host Disease</title>
          <description>Number of patients who exhibited chronic graft-versus-host disease by 1 Year post transplant. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body. Chronic GVHD is an extension of this syndrome.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse experiences were collected during the first 100 days after transplant then 6 months and annually for 3 years.</time_frame>
      <desc>Selected serious adverse experiences (graft failure/autologous recovery, severe acute GVHD (grades III and IV) and death were collected during the first 100 days after transplant then 6 months and annually for 3 years. After day 100, only death or an unexpected adverse event will be reported. Adverse events were not collected in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients Treated With Stem Cell Transplant</title>
          <description>All patients treated with protocol regimen (chemotherapy and stem cell transplant).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Primary graft failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Auto recovery</sub_title>
                <description>Delayed side effects that includes, loss of appetite, nausea and vomiting, changes in vision, mouth and throat soreness, diarrhea, difficulty sleeping and fatigue, infection, hair loss, skin reactions and graft-versus-host disease.</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Change in Neuropsychometric function data is not available. Data would have been noted as descriptive and patient specific, as well as disease specific; not table format. No formal analysis was intended.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Orchard, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2313</phone>
      <email>orcha001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

